Parexel
Parexel International Corporation, commonly known as Parexel, is a leading global biopharmaceutical services provider headquartered in the United States. Founded in 1983, the company has established a strong presence in key operational regions, including Europe and Asia, delivering innovative solutions across the clinical research and regulatory consulting sectors. Specialising in drug development and regulatory affairs, Parexel offers a comprehensive suite of services that includes clinical trial management, biostatistics, and market access strategies. What sets Parexel apart is its commitment to advancing the development of new therapies while ensuring compliance with regulatory standards. With a robust market position, Parexel has achieved numerous milestones, including recognition for its excellence in clinical research. The company continues to play a pivotal role in the biopharmaceutical industry, helping clients navigate the complexities of bringing new drugs to market efficiently and effectively.
DitchCarbon Score
How does Parexel's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Parexel's score of 56 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Parexel's reported carbon emissions
In 2023, Parexel International Corporation reported total carbon emissions of approximately 298,365,000 kg CO2e. This figure includes 2,924,000 kg CO2e from Scope 1 emissions, 6,943,000 kg CO2e from Scope 2 emissions, and a significant 288,498,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming to reduce its absolute Scope 1 greenhouse gas emissions by 42% by 2030, using 2022 as the base year. Additionally, Parexel is committed to reducing its absolute Scope 3 emissions by 25% by the same year. To support these targets, the company plans to source 100% renewable electricity annually through 2030. Parexel has also committed to achieving net-zero emissions across all scopes by 2050, aligning with industry standards for climate action. These initiatives reflect the company's dedication to sustainability and its proactive approach to mitigating climate change impacts within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 15,510,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 11,632,000 | 00,000,000 | 0,000,000 | - | 0,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Parexel is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
